litlas
Log inCreate account

Beverly A. Teicher

Active 1980–2025

109
Papers
17,904
Citations
77
h-index
105
i10-index

Citations

Citations per year for Beverly A. Teicher1981: 7 citations1982: 6 citations1983: 3 citations1984: 8 citations1985: 4 citations1986: 7 citations1987: 20 citations1988: 22 citations1989: 26 citations1990: 36 citations1991: 40 citations1992: 35 citations1993: 39 citations1994: 58 citations1995: 61 citations1996: 53 citations1997: 50 citations1998: 59 citations1999: 60 citations2000: 89 citations2001: 97 citations2002: 71 citations2003: 113 citations2004: 100 citations2005: 100 citations2006: 103 citations2007: 112 citations2008: 112 citations2009: 96 citations2010: 90 citations2011: 103 citations2012: 109 citations2013: 106 citations2014: 116 citations2015: 108 citations2016: 124 citations2017: 149 citations2018: 146 citations2019: 406 citations2020: 499 citations2021: 491 citations2022: 459 citations2023: 311 citations2024: 454 citations2025: 223 citations2026: 3 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,324 citing papers, 32.7% of this breakdownChina: 793 citing papers, 11.2% of this breakdownUnited Kingdom: 453 citing papers, 6.4% of this breakdownGermany: 389 citing papers, 5.5% of this breakdownItaly: 331 citing papers, 4.7% of this breakdownCanada: 249 citing papers, 3.5% of this breakdownJapan: 235 citing papers, 3.3% of this breakdownFrance: 222 citing papers, 3.1% of this breakdownNetherlands: 170 citing papers, 2.4% of this breakdownAustralia: 155 citing papers, 2.2% of this breakdownSpain: 153 citing papers, 2.1% of this breakdownIndia: 131 citing papers, 1.8% of this breakdown
0%32.7%Other 21.1%

Institutions

Fields

  • Medicine50.7%
  • Biochemistry, Genetics and Molecular Biology34.1%
  • Immunology and Microbiology5%
  • Engineering2.8%
  • Materials Science1.7%
  • Computer Science1.3%
  • Other4.4%

Topics

  • Cancer, Hypoxia, and Metabolism3.7%
  • PARP inhibition in cancer therapy3.2%
  • Angiogenesis and VEGF in Cancer2.5%
  • Lung Cancer Research Studies2.2%
  • Cancer Cells and Metastasis2.1%
  • DNA Repair Mechanisms2%
  • Other84.3%

Coauthors

All papers

Open in search
  1. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia

    Authors: Andrei V. Krivtsov, Kathryn Evans, Jayant Y. Gadrey, Benjamin K. Eschle, Charlie Hatton, Hannah J. Uckelmann, Kenneth N. Ross, Florian Perner, Sarah Naomi Olsen, Tara Pritchard, Lisa McDermott, Connor Jones, Duohui Jing, Ali Braytee, Diego Chacon Fajardo, Eric J. Earley, Brian M. McKeever, David A. Claremon, Andrew J. Gifford, Heather Lee, Beverly A. Teicher, John E. Pimanda, Dominik Beck, Jennifer A. Perry, Malcolm A. Smith, Gerard M. McGeehan, Richard B. Lock, Scott A. Armstrong - Cancer Cell 2019 cited by 449

  2. CXCL12 (SDF-1)/CXCR4 Pathway in Cancer

    Authors: Beverly A. Teicher, Simon P. Fricker - Clinical Cancer Research 2010 cited by 1,468

  3. Antibody–drug conjugates for cancer therapy

    Authors: Anish Thomas, Beverly A. Teicher, Raffit Hassan - The Lancet Oncology 2016 cited by 588

  4. PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer

    Authors: Benjamin H. Lok, Eric E. Gardner, Valentina E. Schneeberger, Ai Ni, Patrice Desmeules, Natasha Rekhtman, Elisa de Stanchina, Beverly A. Teicher, Nadeem Riaz, Simon N. Powell, John T. Poirier, Charles M. Rudin - Clinical Cancer Research 2016 cited by 334

  5. Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

    Authors: Junko Murai, Shar-yin N. Huang, Amèlie Renaud, Yiping Zhang, Jiuping Ji, Shunichi Takeda, Joel Morris, Beverly A. Teicher, James H. Doroshow, Yves Pommier - Molecular Cancer Therapeutics 2013 cited by 758

  6. SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures

    Authors: Camille Tlemsani, Lőrinc Sándor Pongor, Fathi Elloumi, Luc Girard, Kenneth E. Huffman, Nitin Roper, Sudhir Varma, Augustin Luna, Vinodh N. Rajapakse, Robin Sebastian, Kurt W. Kohn, Julia Krushkal, Mirit I. Aladjem, Beverly A. Teicher, Paul S. Meltzer, William C. Reinhold, John D. Minna, Anish Thomas, Yves Pommier - Cell Reports 2020 cited by 168

  7. The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models

    Authors: Nathan M. Kendsersky, Jarrett M. Lindsay, E. Anders Kolb, Malcolm A. Smith, Beverly A. Teicher, Stephen W. Erickson, Eric J. Earley, Yaël P. Mossé, Daniel Martínez, Jennifer Pogoriler, Kateryna Krytska, Khushbu Patel, David Groff, Matthew Tsang, Samson Ghilu, Yifei Wang, Steven Seaman, Yang Feng, Brad St. Croix, Richard Görlick, Raushan T. Kurmasheva, Peter J. Houghton, John M. Maris - Clinical Cancer Research 2021 cited by 122

  8. Antibody Conjugate Therapeutics: Challenges and Potential

    Authors: Beverly A. Teicher, Ravi Chari - Clinical Cancer Research 2011 cited by 422

  9. Immuno-transcriptomic profiling of extracranial pediatric solid malignancies

    Authors: Andrew S. Brohl, Sivasish Sindiri, Jun S. Wei, David Milewski, Hsien-Chao Chou, Young Song, Xinyu Wen, Jeetendra Kumar, Hue V. Reardon, Uma Mudunuri, Jack Collins, Sushma Nagaraj, Vineela Gangalapudi, Manoj Tyagi, Yuelin J. Zhu, Katherine E. Masih, Marielle E. Yohe, Jack F. Shern, Yue Qi, Udayan Guha, Daniel Catchpoole, Rimas J. Orentas, Igor B. Kuznetsov, Nicolás J. Llosa, John A. Ligon, Brian Turpin, Daniel Leino, Shintaro Iwata, Irene L. Andrulis, Jay S. Wunder, Sílvia Regina Caminada de Toledo, Paul S. Meltzer, Ching C. Lau, Beverly A. Teicher, Heather Magnan, Marc Ladanyi, Javed Khan - Cell Reports 2021 cited by 71

  10. Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression

    Authors: Eric C. Polley, Mark W. Kunkel, David M. Evans, Thomas Silvers, René Delosh, Julie Laudeman, Chad Ogle, Russell Reinhart, Michael Selby, John Connelly, Erik Harris, Nicole Fer, Dmitriy Sonkin, Gurmeet Kaur, Anne Monks, Shakun Malik, Joel Morris, Beverly A. Teicher - JNCI Journal of the National Cancer Institute 2016 cited by 173

  11. Antibody-drug Conjugate Targets, Drugs, and Linkers

    Authors: Beverly A. Teicher, Joel Morris - Current Cancer Drug Targets 2022 cited by 34

  12. Comprehensive characterization of the Published Kinase Inhibitor Set

    Authors: Jonathan M. Elkins, Vita Fedele, M. Szklarz, Kamal R. Abdul Azeez, E. Salah, Jowita Mikolajczyk, Sergei Romanov, Nikolai Sepetov, Xi‐Ping Huang, Bryan L. Roth, Ayman Al Haj Zen, Denis Fourches, Eugene Muratov, Alex Tropsha, Joel Morris, Beverly A. Teicher, Mark W. Kunkel, Eric C. Polley, Karen Lackey, Francis Atkinson, John P. Overington, Paul Bamborough, Susanne Müller, Daniel J. Price, Timothy M. Willson, David H. Drewry, Stefan Knapp, William J. Zuercher - Nature Biotechnology 2015 cited by 350

  13. Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets

    Authors: Julia Krushkal, Thomas Silvers, William C. Reinhold, Dmitriy Sonkin, Suleyman Vural, John Connelly, Sudhir Varma, Paul S. Meltzer, Mark W. Kunkel, Annamaria Rapisarda, David M. Evans, Yves Pommier, Beverly A. Teicher - Clinical Epigenetics 2020 cited by 87

  14. Hypoxia and drug resistance

    Authors: Beverly A. Teicher - Cancer and Metastasis Reviews 1994 cited by 563

  15. OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL

    Authors: Kathryn Evans, JianXin Duan, Tara Pritchard, Connor Jones, Lisa McDermott, Zhaohui Gu, Cara E. Toscan, Narimanne El-Zein, Chelsea Mayoh, Stephen W. Erickson, Yuelong Guo, Fanying Meng, Donald Jung, Komal S. Rathi, Kathryn G. Roberts, Charles G. Mullighan, Chi‐Sheng Shia, Tillman Pearce, Beverly A. Teicher, Malcolm A. Smith, Richard B. Lock - Clinical Cancer Research 2019 cited by 53

  16. TGFβ-Directed Therapeutics: 2020

    Authors: Beverly A. Teicher - Pharmacology & Therapeutics 2020 cited by 87

  17. CD248: A therapeutic target in cancer and fibrotic diseases

    Authors: Beverly A. Teicher - Oncotarget 2019 cited by 79

  18. Tumor Evasion of the Immune System by Converting CD4+CD25− T Cells into CD4+CD25+ T Regulatory Cells: Role of Tumor-Derived TGF-β

    Authors: Victoria C. Liu, Larry Wong, Thomas L. Jang, Ali Shah, Irwin Park, Ximing J. Yang, Qiang Zhang, Scott Lonning, Beverly A. Teicher, Chung Lee - The Journal of Immunology 2007 cited by 440

  19. Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization

    Authors: Rebecca G. Bagley, Nakayuki Honma, William Weber, Paula Boutin, Cécile Rouleau, Srinivas Shankara, Shiro Kataoka, Isao Ishida, Bruce Roberts, Beverly A. Teicher - Microvascular Research 2008 cited by 115

  20. Proteasome inhibitors

    Authors: Beverly A. Teicher, Joseph E. Tomaszewski - Biochemical Pharmacology 2015 cited by 168

  21. Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

    Authors: Caitlin D. Lowery, Michele Dowless, Matthew Renschler, Wayne Blosser, Alle B. VanWye, Jennifer R. Stephens, Philip W. Iversen, Aimee Bence Lin, Richard P. Beckmann, Kateryna Krytska, Kristina A. Cole, John M. Maris, Douglas S. Hawkins, Brian P. Rubin, Raushan T. Kurmasheva, Peter J. Houghton, Richard Görlick, E. Anders Kolb, Min H. Kang, C. Patrick Reynolds, Stephen W. Erickson, Beverly A. Teicher, Malcolm A. Smith, Louis F. Stancato - Clinical Cancer Research 2018 cited by 80

  22. ABBV-085, Antibody–Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium

    Authors: Pooja Hingorani, Michael Roth, Yifei Wang, Wendong Zhang, Jonathan Gill, Douglas J. Harrison, Beverly A. Teicher, Stephen W. Erickson, Gregory J. Gatto, Malcolm A. Smith, E. Anders Kolb, Richard Görlick - Molecular Cancer Therapeutics 2020 cited by 37

  23. Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies

    Authors: Qi Lin, Holly Lindsay, Mari Kogiso, Yuchen Du, Frank Braun, Huiyuan Zhang, Lei Guo, Sibo Zhao, Sarah G. Injac, Patricia Baxter, Jack Su, Sophie Xiao, Stephen W. Erickson, Eric J. Earley, Beverly A. Teicher, Malcolm A. Smith, Xiao‐Nan Li - Laboratory Investigation 2021 cited by 26

  24. Integrative epigenomic analyses of small cell lung cancer cells demonstrates the clinical translational relevance of gene body methylation

    Authors: Lőrinc Sándor Pongor, Camille Tlemsani, Fathi Elloumi, Yasuhiro Arakawa, Ukhyun Jo, Jacob Gross, Sara Mosavarpour, Sudhir Varma, Rahul K. Kollipara, Nitin Roper, Beverly A. Teicher, Mirit I. Aladjem, William C. Reinhold, Anish Thomas, John D. Minna, Jane E. Johnson, Yves Pommier - iScience 2022 cited by 23